Your session is about to expire
← Back to Search
Monoclonal Antibodies
RO7567132 + Atezolizumab for Cancer
Phase 1
Recruiting
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Availability and willingness to provide a mandatory archival tumor specimen or (if not available) a fresh baseline biopsy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 and life expectancy of at least 12 weeks
Must not have
Known CNS tumors or metastases and leptomeningeal metastases
Known clinically significant liver disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test the safety and effectiveness of a new drug called RO7567132 on its own and combined with atezolizumab in adults with advanced solid tumors that don't respond
Who is the study for?
Adults over 18 with advanced solid tumors, for whom standard treatments failed or aren't suitable. They must be relatively active (ECOG status 0-1), expected to live at least 12 weeks, and able to provide a tumor sample. Participants need good heart, blood, liver, and kidney function and women must not be pregnant.
What is being tested?
The trial is testing RO7567132 alone and combined with Atezolizumab in patients with advanced cancers. It aims to assess the safety of these drugs, how they affect the body (PK/PD), and their initial effectiveness against cancer.
What are the potential side effects?
Potential side effects may include immune-related reactions due to drug-induced activation of the immune system against normal tissues; typical symptoms could involve fatigue, skin issues or inflammation affecting various organs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can provide a sample of my tumor for the study.
Select...
I am mostly active and my doctor expects me to live at least 12 more weeks.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have tumors or cancer spread to my brain or spinal cord.
Select...
I have a significant liver condition.
Select...
I have a history of serious heart or brain blood vessel problems.
Select...
I have or had an autoimmune disease.
Select...
I do not have any serious, uncontrolled infections.
Select...
I have no lasting side effects worse than mild from previous treatments.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part II: RO7567132 Backfill With AtezolizumabExperimental Treatment1 Intervention
Group II: Part I: RO7567132 Dose Escalation With or Without AtezolizumabExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Hoffmann-La RocheLead Sponsor
2,463 Previous Clinical Trials
1,102,947 Total Patients Enrolled
Clinical trailsStudy DirectorHoffmann-La Roche